Market research
4564.TSE OncoTherapy Science, Inc
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.3
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3202150003
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.3
About
About OncoTherapy Science, Inc
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. Its pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, the company is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4564.TSE discussion.
5 years, 6 months ago
OncoTherapy Science, Inc is currently in a long term downtrend where the price is trading 13.2% below its 200 day moving average.
From a valuation standpoint, the stock is 3.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 68.3.
OncoTherapy Science, Inc's total revenue rose by 3.9% to $59M since the same quarter in the previous year.
Its net income has increased by 17.9% to $-426M since the same quarter in the previous year.
Based on the above factors, OncoTherapy Science, Inc gets an overall score of 3/5.